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BACKGROUND/INTRODUCTION
In 1935, R.A. Fisher predicted the use of
genetic information in assessing insurance risks
[1]. Several genetic tests are now available
routinely. Most genetic tests likely to be utilised
by insurers are for later onset conditions, such as
cancer, and neurological disease. Huntington
disease (HD), an autosomal dominant disorder,
has been a model for this type of testing. Several
ethical and legal problems already have been
recognised [2,3]. In 1995, the American Society
of Human Genetics published a statement to help
understanding of insurance issues [4].  Clearly,
there is a difference between more highly
penetrant autosomal dominant diseases such as
HD, and such diseases as breast cancers. Life
tables and penetrance have been worked out for
HD and it is possible to predict the age of death
within a narrow range. Cancers due to single
genes such as breast cancer, which constitute
only 5–10% of a predominantly non familial
common cancer, present more difficulty, as
accurate lifetime risk tables are unavailable or are
difficult to compile with penetrance data of
limited accuracy. In polygenic diseases such as
Alzheimer disease and diabetes, gene markers
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may suggest a likely cause of death but not a
specific lifetime prediction. Experience with non
‘genetic’ conditions, such as AIDS are also
relevant, as homozygous carriers of the CCR5-32
AIDS allele show nearly complete resistance to
HIV infection [5].
Several European countries have no legislation
or guidelines on insurance and genetic testing.
Countries that have some guidelines, have a
moratorium on the use of genetic tests. For
example, in France, the moratorium is up to five
years, whilst in the Netherlands, it has been
extended indefinitely. Once a moratorium has
been introduced, it is difficult to find sufficient
scientific evidence to justify lifting a ban on the
use of genetic testing in underwriting practice
[6].
Definition of a genetic test
A genetic test has been defined as “an
examination of the chromosome, DNA or RNA
to find out if there is an otherwise undetectable
disease related genotype, which may indicate an
increased chance of that individual developing a
specific disease in the future” [7].
The UK advisory committee on genetic testing
(ACGT) [8] defines it as “a test to detect the
presence or absence of, or change in, a particular
gene or chromosome”.
What percentage of policies are affected?
In the UK, 95–97% of life insurance policies
are accepted at no increased premium. Only
1. Insurance companies will not insist on genetic tests.
2. Genetic test results will only affect insurance if they show a clearly increased risk of illness or death. A low
increase in risk will not necessarily affect the premium.
 
3. Insurance companies will always seek expert medical advice when assessing the impact of genetic test results
on insurance.
 
4. Insurers may take account of a test result only when reliability and relevance have been established.
 
5. Applicants for insurance will not be asked to take a genetic test, but existing test results should be given to the
insurance company when it asks a relevant question, unless it has said this information is not required.
 
6. Existing genetic test results need not be disclosed in applications for life insurance up to £100,000 which are
directly linked to a new mortgage for the purchase of a house to be occupied by the applicant(s).
 
7. An applicant will not be required to disclose the result of a genetic test undertaken by another person (such as
a blood relative), and one person’s test information will not affect another person’s application.
 
8. The reason for an increased premium or rejection of an insurance application will be provided to the
applicant’s doctor on request.
 
9. Insurers will not “cherry pick” by offering a “preferred life” lower than normal premiums on the basis of their
genetic test results.
 
10. An independent adjudication tribunal is being set up to consider complaints, which are unresolved.
 
11. Each year chief executives will need to demonstrate how they have complied with the code.
Fig. 1. Association of British Insurers principles for genetic testing.
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about 1% are declined, and 2–4% are rated up
[9,10]. There is no analysis of these figures for
specific diseases.  The main reason for refusal or
‘loaded’ premiums is the above average sum
assured, and not the type of ‘high risk’ individual
assessed. Risks for insurers will be small if the
policy value is low [10], for example under
£100,000.
THE UK EXPERIENCE
In the UK, insurance recommendations are
interesting because it is the only country in
Europe to have had a recent change in insurance
recommendations. These changes have been
driven mainly by insurance companies. This
contrasts with the Netherlands and other EU
countries which have legislation generated by the
government.
An Association of British Insurers (ABI) code
of practice for genetic testing, [7] came into
effect in January 1998. The code has several
important features (Figure 1) and applies to all
insurance, including life, permanent health,
critical illness, long term care and medical
expenses. Most ‘relevant’ UK insurance is
predominantly life insurance linked to personal
pensions, and property insurance [mortgage
cover]. As the UK National Health Service
provides free health care, health insurance is less
frequently purchased than in the USA, although
there has been a recent increase in sales of
personal health insurance cover policies. The
situation differs from the USA insurance market,
which is dominated by private health insurance.
The role of the Human Genetics Advisory
Commission in the UK
The Human Genetics Advisory Commission
(HGAC), was established in December 1996 as a
non-statutory advisory body to report to the
government on various developments in genetics.
The first HGAC report was published in
1. A permanent ban on the use of genetic testing is not appropriate. Recommendation is for introduction of a
moratorium on genetic testing for at least 2 years.
 
2. There is not sufficient predictive ability of genetic tests at the moment to allow accurate risk assessment.
 
3. The life insurance industry could currently withstand limited adverse selection if non-disclosure of test results
was current policy.
 
4. There is a perception of unacceptable discrimination — this may deter testing that may lead to beneficial
treatment.
 
5. Arrangements for confidentiality of data are adequate under current practice.
 
6. No company should require taking of a test as a prerequisite of obtaining cover.
 
7. Increased research and collaboration between industry and science is required to improve knowledge of
actuarial implications of genetic factors.
 
8. There should be a robust appeals procedure as part of any new system.
 
9. Recommendations are primarily relating to life insurance but the principles above should apply to other types
of health insurance.
Fig. 2. Recommendations on genetic testing & insurance of the Human Genetics Advisory Commission of the UK.
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December 1997 [11]. The commission has 10
members who include representation from
clinical geneticists, the pharmaceutical industry,
media, patient support groups, legal and lay
persons. It also includes the chairman of the gene
therapy advisory committee (GTAC), and of the
Advisory committee on genetic testing (ACGT).
The report recommended a two-year moratorium
on genetic testing. Its conclusions are shown in
Figure 2.  The Association of British Insurers
(ABI), also reported their recommendations at the
same time as the HGAC.
How have the recommendations been
received?
The Government press release stated that
“People who have taken a genetic test can be
confident that they will get fair treatment from
insurers”. The ABI in their news release [7]
stated that  “The insurance industry is very
supportive of what the Government is trying to
achieve…”. The Sunday Times (London) of the
8th November 1998, stated “DTI code leaves
insurers free to create ‘genetic underclass’ ”.
The Government plans to use a newly formed
genetics insurance advisory committee (GIAC),
[12] to validate genetic tests proposed by the
ABI [13,14]. Already the ABI has produced
matrices of autosomal dominant, autosomal
recessive and X-linked recessive diseases for
potential validation. The list includes
Huntington disease, multiple endocrine
neoplasia (MEN-2), breast cancer (BRCA1 & 2
genes), familial adeno-matous polyposis coli
(FAP), Alzheimer disease, hereditary motor and
sensory neuropathy (HMSN) and myotonic
dystrophy. The UK has therefore become the
first country in Europe in which regulations for
genetic testing in the context of insurance are
being shaped by the industry, even though the
GIAC will have a role in validating the tests
proposed by the ABI. How this relationship will
work out in practice remains to be seen, and
may require extension of existing discrimination
laws to include those at risk of a genetic
disorder or the introduction of entirely new
legislation.
THE BROADER EUROPEAN
EXPERIENCE
There is a plethora of measures in other
European countries. In the Netherlands, it is
considered that strict regulation will be needed.
In 1995, a 5-year moratorium was extended
indefinitely and insurers have agreed not to use
genetic tests or existing genetic information for
policies below NLG 300,000. Individual
responsibility is seen as being extremely
important. Limitations on the collection and use
of genetic information are derived from the
medical treatment and medical checks acts.
In Austria, the 1994 gene technology law
states that employers and insurers are forbidden
to obtain, request accept or use results of genetic
analyses.
In Belgium, a 1992 Non-marine insurance law
allows medical examinations etc. to be based
only on past medical history establishing the
applicant’s medical state, and not on genetic
analysis techniques capable of determining future
state of health.
In France, the 1994 French Federation of
Insurance Companies (FFSA) issued a statement
saying that for 5 years, the FFSA will not use
genetic information when determining
applicants’ insurability, even if favourable
information is brought by applicants.
In Norway, a 1994 biotechnology law allows
strict use of genetic tests. It states that it is
‘forbidden to request, receive, retain or make use
of genetic information from a genetic test result,
and it is forbidden to ascertain if a genetic test
has been performed’. This may not apply to
diagnostic tests.
In 1997, Poland introduced a law, which
established a general inspectorate for personal
data protection. The German insurance system
does not use genetic information to reach
decisions about awarding coverage.  There is no
legislation in Hungary, Ireland, Italy, Portugal or
Spain.
There is little doubt that most members of the
European Union will have legislation in relation
to the use of genetic information in the near
future. Following the national referendum in
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Switzerland in June 1998, to limit genetic
experimentation, in which the vote went against
the proposal, there are no plans to introduce
genetic legislation for the time being.
LEGISLATION ON GENETIC
TESTING IN OTHER COUNTRIES
Australia had draft guidelines in July 1997,
and these are currently being revised. Canada has
no legislation. New Zealand issued guidelines in
April 1997 on insurance and genetic tests. The
situation in the USA is covered partly by the
Discrimination act, 1996. Current bills passing
through the US government include one on
genetic information & non-discrimination in
health insurance [15,16].
Genetic testing in established cancer genetics
disorders allows prevention
Genetic tests have been used in the diagnosis
and management of cancer for several years [17,
18]. For example, in multiple endocrine neoplasia
type 2A (MEN2A), familial medullary thyroid
cancer can result in early death by metastatic
spread, presymptomatic testing has led to
prophylactic thyroidectomy in high risk
individuals in families in which a MEN2A gene
mutation has been identified. Some clinicians
have used DNA testing alone without the use of
other investigations in such families [19]. Several
children under the age of 10 years have been
identified as carriers, with pathological
confirmation of focal carcinoma. Thyroidectomy
is “curative”, however, such results are not easily
extrapolated to later onset breast or colon
cancers. There is a danger that patients may be
reluctant to undergo genetic testing if insurance
companies penalise gene carriers, rather than
encouraging them to prolong their life
expectancy by prophylactic surgery [20]. Ethical
and legal implications may be an added
difficulty. The duty to warn under law has been
raised [21] Already one physician has been sued
by the child of an affected MEN2A patient
because she was not informed that the condition
was hereditary [22]. Several European countries
are developing guidelines for screening of breast
cancer gene carriers and for the organisation of
cancer genetic clinics [23].
Benefits of genetic testing
The finding of negative test results (i.e. non-
gene carriers) has been used to lower already
high premiums, as in Austria [24]. However, as
in the UK, insurance companies cannot insist that
applicants should have genetic tests. Many
individuals at risk and on a higher premium, will
organise genetic tests at their own expense.
Confirmation by genetic testing of a disease, such
as Friedreich ataxia or HD does not increase the
existing premium, but a negative test result has
led to a reduced premium for some applicants.
Some insurers consider that genetic
information is not essential for underwriting life
insurance, and are not requesting information
about genetic tests. Most applicants who were
requested to provide further information were not
rated at a higher premium or rejected. Some
companies consider they can absorb this small
extra load — only 1 in 20 policies are actually
claimed on death, which is not an excessive
amount.
Over the counter genetic tests
There has not been a large demand for
commercial genetic testing in the UK. Over the
counter testing is regulated by the ACGT, [8,25].
In the UK, it is considered that genetic testing
services should be provided within the NHS [25].
It is important that the interpretation of genetic
tests should be provided by an expert such as a
clinical geneticist or other physician.
The potential for discrimination
Discrimination is an increasing problem,
especially in employment. The Council of
Europe’s Convention on Human Rights and
Biomedicine states that “Any form of
discrimination against a person on grounds of his
or her genetic heritage is prohibited”. In the UK,
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applicants for training for military aircrews are
biochemically screened for sickle cell disease and
sickle cell trait. This approach is designed to
protect the individual from the potentially
catastrophic effects of sickling provoked by low
oxygen pressures in flight. In the USA, it is not a
bar to air crew training. Is this the thin end of the
wedge? In EU countries, legislation is limited to
broad statements. Our survey of European
genetic centres involved in breast cancer testing
showed that all the UK centres surveyed had had
patients who refused testing because of fear of
penalty or being unable to obtain insurance.
Some 25% of UK centres had experience of
patients who refused genetic testing because of
fear of employment discrimination [26]. Most of
the non-UK centres did not appear to have any
major discrimination problems. This finding
supports the HGAC statement that “there is a
perception of unacceptable discrimination in the
UK” [12]. The UK does have legislation on
discrimination. The ‘disability discrimination act
1995’ deals with this issue and may conflict with
some of the ABI guidelines, as it forbids
employers discriminating against those who are
disabled. However the definition of disabled does
not cover asymptomatic individuals with a
predisposition to genetic illness. ‘Fair’
discrimination is allowed in relation to insurance,
i.e. discrimination is justified as long as it is
supported with actuarial evidence. Thus, although
it would be unlawful to refuse insurance, a
premium commensurate with the risk would be
allowed.
The future
The situation may change greatly with the
patenting of genes by commercial companies.
Already BRCA1 and BRCA2 gene tests have
been patented by Myriad Genetics in the US, and
if Myriad’s European BRCA1 and BRCA2
patents are granted, costs of testing may increase
and availability limited to certain European
laboratories. Currently UK health insurance
companies do not pay for or reimburse costs for
genetic tests. Patents for hereditary non-polyposis
cancer genes and the p16 melanoma gene are
held by Human Genome Sciences and Sequana
Therapeutics respectively [27]. Undoubtedly
more patent granting is in the pipeline. Already,
in the USA, it is difficult to obtain a BRCA1 &
BRCA2 test without paying $2400 through a
Myriad Genetics licensed laboratory. In the USA,
several insurance companies will often reimburse
the patient (albeit on the insurance companies
testing terms).
At the moment, general public concern about
the activities of insurance companies is limited. It
appears that governments are not intervening
with strict regulations. However, perhaps with
the expansion of available genetic tests and more
particularly, when genetic tests can more
accurately predict susceptibility to multifactorial
disease, the situation may change. Currently,
insurance companies cannot insist on the
disclosure of results of genetic tests or insist that
patients undergo genetic testing. The stringent
requirements for confidentiality and privacy need
to be maintained by legislation as each one of us
may carry some potentially ‘abnormal’ genes
which in the future, may be more easily
identifiable with completion of the human
genome project.
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